Recent developments and new applications of tandem mass spectrometry in newborn screening

Current Opinion in Pediatrics

Volumn 16, Issue 4, 2004, Pages 427-433

  Rinaldo, Piero ^a,b   Tortorelli, Silvia ^a   Matern, Dietrich ^a  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

New inborn errors of metabolism; Newborn screening; Second tier test; Tandem mass spectrometry

Indexed keywords

ACYLCARNITINE; AMINO ACID; BIOCHEMICAL MARKER; PALMITOYL COENZYME A HYDROLASE;

AMINO ACID ANALYSIS; BRAIN DISEASE; CITRULLINEMIA; CLINICAL FEATURE; COHORT ANALYSIS; CONGENITAL ADRENAL HYPERPLASIA; CONGENITAL HYPOTHYROIDISM; CORRELATION ANALYSIS; DISEASE MARKER; ENZYME DEFICIENCY; EPIDEMIOLOGICAL DATA; GENOTYPE; HEALTH PROGRAM; HUMAN; NEWBORN SCREENING; OUTCOMES RESEARCH; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TANDEM MASS SPECTROMETRY;

ADRENAL HYPERPLASIA, CONGENITAL; CALCIUM-BINDING PROTEINS; HUMANS; INFANT, NEWBORN; MALONATES; MASS SCREENING; MASS SPECTROMETRY; METABOLISM, INBORN ERRORS; NEONATAL SCREENING; ORGANIC ANION TRANSPORTERS; OXIDOREDUCTASES; PREDICTIVE VALUE OF TESTS;

EID: 3442875863     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000133635.79661.84     Document Type: Review

References (37)

1. Matern D, Rinaldo P: Newborn screening: opportunities and challenges of tandem mass spectrometry. Clin Lab News 2003, 29:12-15.
2. Jensen UG, Brandt NJ, Christensen E, et al.: Neonatal screening for galactosemia by quantitative analysis of hexose monophosphates using tandem mass spectrometry: a retrospective study. Clin Chem 2001, 47:1364-1372.
3. Lacey J, Minutti CZ, Magera MJ, et al.: Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry. Clin Chem 2004, 50:621-625. Report of a new method that can eliminate approximately 90% of false positive results caused by stress, prematurity, and antibody cross-reactivity.
4. Chace DH, Kalas TA, Naylor EW: Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin Chem 2003, 49:1797-1817. This is a comprehensive and informative review on the subject of MS/MS and newborn screening.
5. Khoury MJ, McCabe L, McCabe ERB: Population screening in the age of genomic medicine. N Engl J Med 2003, 348:50-58.
6. National Newborn Screening Genetic Resources Center web site: http://genes-r-us.uthscsa.edu
7. Wilcken B, Wiley V, Hammond J, et al.: Screening for newborn errors of metabolism by tandem mass spectrometry. N Engl J Med 2003, 348:2304-2312. An elegantly designed outcome study made possible by the centralized provision of laboratory and clinical services in New South Wales, Australia.
8. Schulze A, Lindner M, Kohlmüller D, et al.: Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. Pediatrics 2003, 111:1399-1406. Good outcome study in a region at the forefront of newborn screening by MS/MS.
9. Hoffman GF, von Kries R, Klose D, et al.: Frequencies of inherited organic acidurias and disorders of mitochondrial fatty acid transport and oxidation in Germany. Eur J Pediatr 2004, 163:76-80.
10. Waisbren SE, Albers S, Amato S, et al.: Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA 2003, 290:2564-2572. This is a valuable contribution to the understanding of the unintended consequences of expanded newborn screening, particularly the negative impact of false positive results.
11. Kiernan UA, Black JA, Williams P, et al.: High-throughput analysis of hemoglobin from neonates using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 2002, 48:947-949.
12. Li Y, Brockmann K, Turecek F, et al.: Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for Krabbe disease. Clin Chem 2004, 50:638-640. A new method for the determination of galactocerebroside β-galactosidase in neonatal blood spots.
13. Meikle PJ, Hopwood JJ: Lysosomal storage disorders: emerging therapeutic options require early diagnosis. Eur J Pediatr 2003, 162(Suppl 1):S34-S37. A recent contribution from the leading group in the field of lysosomal storage disease screening.
14. Minutti CZ, Lacey JM, Magera MJ, et al.: Steroid profiling by tandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab 2004, in press.
15. Saheki T, Kobayashi K: Mitochondrial aspartate glutamate carrier (citrin) deficiency as the cause of adult-onset type II citrullinemia (CTLN2) and idiopathic neonatal hepatitis (NICCD). J Hum Genet 2002, 47:333-341.
16. Ohura T, Kobayashi K, Abukawa D, et al.: A novel inborn error of metabolism detected by elevated methionine and/or galactose in newborn screening: neonatal intrahepatic cholestasis caused by citrin deficiency. Eur J Pediatr 2003, 162:317-322. An interesting study that uncovers likely diagnostic oversight of a recently described metabolic defect.
17. Burlina AB, Dionisi-Vici C, Bennett MJ, et al.: A new encephalopathy with ethylmalonic aciduria and normal fatty acid oxidation in fibroblasts. J Pediatr 1994, 124:79-86.
18. Tiranti V, D'Adamo P, Briem E, et al.: Ethylmalonic encephalopathy is caused by mutations in ETHE1, a gene encoding a mitochondrial matrix protein. Am J Hum Genet 2004, 74:239-252. The characterization of a new mitochondrial disorder presenting with a very complex clinical phenotype. This discovery is likely to pave the way to the understanding of a previously unknown metabolic pathway.
19. McGowan KA, Nyhan WL, Barshop BA, et al.: The role of methionine in ethylmalonic encephalopathy with petechiae. Arch Neurol 2004, 61:570-574. A potential breakthrough in the understanding of the primary defect of ethylmalonic encephalopathy.
20. Roe CR, Cederbaum SD, Roe DS, et al.: Isolated isobutyryl-CoA dehydrogenase deficiency: an unrecognized defect in human valine metabolism. Mol Genet Metab 1998, 65:264-271.
21. Koeberl DD, Young SP, Gregersen N, et al.: Rare disorders of metabolism with elevated butyryl- and isobutyryl-carnitine detected by tandem mass spectroscopy newborn screening. Pediatr Res 2003, 54:219-223. A valuable contribution to the differential diagnosis of uncommon disorders.
22. Gibson KM, Terry G, Burlingame TG: 2-Methylbutyryl-coenzyme A dehydrogenase deficiency: a new inborn error of L-isoleucine metabolism. Pediatr Res 2000, 47:830-833.
23. Matern D, He M, Berry SA, et al.: Prospective diagnosis of 2-methylbutyryl-CoA dehydrogenase deficiency in the Hmong population by newborn screening using tandem mass spectrometry. Pediatrics 2003, 112:74-78. Report of the high incidence in the Hmong population of an otherwise extremely rare disorder.
24. 4-acylcarnitine concentration in newborn blood spots. Mol Genet Metab 2003, 78:239-246. A valuable contribution to the understanding of a poorly understood condition.
25. Corydon MJ, Vockley J, Rinaldo P, et al.: Role of common gene variations in the molecular pathogenesis of short-chain acyl-CoA dehydrogenase deficiency. Pediatr Res 2001, 49:18-23.
26. Bok LA, Vreken P, Wijburg FA, et al.: Short-chain acyl-CoA dehydrogenase deficiency: studies in a large family adding to the complexity of the disorder. Pediatrics 2003, 112:1152-1155.
27. Matern D, Rinaldo P: Medium-chain acyl-coenzyme A dehydrogenase deficiency. In: GeneReviews: Genetic Disease Online Reviews at GeneTests-GeneClinics [database online: Last update January 27, 2003]. Copyright, University of Washington, Seattle. Available at http://www. geneclinics.org.
28. Andresen BS, Dobrowolski SF, O'Reilly L, et al.: Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. Am J Hum Genet 2001, 68:1408-1418.
29. Lehotay DC, LePage J, Thompson JR, et al.: Blood acylcarnitine levels in normal newborns and heterozygotes for medium-chain acyl-CoA dehydrogenase deficiency: a relationship between genotype and biochemical phenotype? J Inherit Metab Dis 2004, 27:81-88. A valuable contribution to the debate on the existence, or not, of genotype/phenotype correlations in a disorder that is greatly influenced by diet and environment.
30. Rinaldo P, Matern D, Bennett MJ: Fatty acid oxidation disorders. Ann Rev Physiol 2002; 64:16.1-26.
31. Spiekerkoetter U, Sun B, Zytkovicz T, et al.: MS/MS-based newborn and family screening detects asymptomatic patients with very-long-chain acyl-CoA dehydrogenase deficiency. J Pediatr 2003, 143:335-342. An example of the impact of newborn screening on our understanding of the natural history of a genetic condition.
32. Ensenauer RE, Vockley J, Grünert S, et al.: Novel phenotype of isovaleric acidemia associated with a common mutation identified in patients diagnosed by newborn screening. Mol Genet Metab 2004, 81:160-161 [abstract]. An example of the impact of newborn screening on our understanding of the natural history of a genetic condition.
33. Pandor A, Eastham J, Beverley C, et al.: Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review. Health Technol Assess 2004, 8(12). A vast overview of the clinical and financial aspects of expanded newborn screening.
34. United States General Accounting Office: Newborn screening: Characteristics of state programs. GAO-03-449 available at www.gao.gov/cgi-bin/ getrpt?GAO-03-449.
35. American College of Obstetricians and Gynecologists Committee on Genetics: Opinion No. 287: Newborn screening. Obstet Gynecol 2003, 102:887-889.
36. Howell RR, van Dyke P, Alexander D: Newborn screening: future promise. Pediatr Res 2004, 55(Suppl 2):276A [abstract]. A "sneak preview" of the ACMG/HRSA report to be released in the all of 2004.
37. Federal Register April 20, 2004/Notices; 69(76):21140.